Madrigal Pharmaceuticals (MDGL) Common Equity (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Common Equity data on file, last reported at $543.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $543.5 million, down 23.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $543.5 million (down 23.53% YoY), and the FY2025 annual result was $602.7 million, down 20.11% from the prior year.
• Common Equity slipped to $543.5 million in Q1 2026 per MDGL's latest filing, from $602.7 million in the prior quarter.
• Over five years, Common Equity peaked at $857.1 million in Q2 2024 and troughed at $10.7 million in Q3 2022.
• A 5-year average of $443.3 million and a median of $543.5 million in 2026 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity plunged 95.46% in 2022, then surged 3392.99% in 2024.
• A 5-year view of Common Equity shows it stood at $197.4 million in 2022, then jumped by 105.35% to $405.3 million in 2023, then jumped by 86.11% to $754.4 million in 2024, then fell by 20.11% to $602.7 million in 2025, then fell by 9.83% to $543.5 million in 2026.
• Business Quant data shows MDGL's Common Equity at $543.5 million in Q1 2026, $602.7 million in Q4 2025, and $625.7 million in Q3 2025.